BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Casi Pharmaceuticals, Inc. CASIF
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$20.7M
▼ 27.4% vs FY2024
EPS · FY25
$-2.59
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-232.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 20.7M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 232 cents on every revenue dollar this year.
Per share
USD -2.59
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-217.3%
Net margin-232.0%
Return on assets-121.2%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+6.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−21.7%
+6.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 25.6M
total assets, end of FY2025
Total assetsUSD 25.6M
EquityUSD -37.3M
CashUSD 5.6M
Gross debtUSD 19.2M
Net debtUSD 13.6M
Current ratio0.27×
Net debt stands at -36% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
Income tax $B
·
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.59
−2.56
−2.02
−3.01
−2.69
−4.37
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
−301.8
−78.4
−63.6
−44.2
−59.2
Shares out B
0.02
0.02
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed